Immunovant (NASDAQ:IMVT) Insider Sells $290,977.83 in Stock

Immunovant, Inc. (NASDAQ:IMVT) insider Tuyl Christopher Van sold 10,813 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $26.91, for a total transaction of $290,977.83. Following the completion of the sale, the insider directly owned 149,930 shares of the company’s stock, valued at approximately $4,034,616.30. The trade was a 6.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Immunovant Stock Performance

NASDAQ:IMVT opened at $26.68 on Monday. Immunovant, Inc. has a 52 week low of $12.72 and a 52 week high of $27.69. The firm’s 50-day simple moving average is $22.68 and its 200 day simple moving average is $18.47. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -9.39 and a beta of 0.56.

Immunovant (NASDAQ:IMVT) last announced its earnings results on Monday, November 10th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.01). During the same period in the previous year, the business posted ($0.74) EPS. Sell-side analysts anticipate that Immunovant, Inc. will post -2.69 EPS for the current year.

Trending Headlines about Immunovant

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Zacks Research raised multiple near‑ and longer‑term EPS estimates for IMVT (several quarter and FY lifts, including FY2028 to -$2.68 from -$2.83 and FY2027 to -$3.05 from -$3.12). The revisions are modest but signal slightly improved profitability expectations that can support valuation. Read More.
• Positive Sentiment: Analyst target/coverage momentum: recent analyst notes (including Goldman Sachs raising its target to $28 and several buy/hold ratings) help underpin investor confidence and provide a nearer‑term price target ceiling above current levels. Read More.
• Neutral Sentiment: Institutional activity cited by MarketBeat shows varied small buys and holdings growth by several funds; about 47% of shares are institutionally owned — a neutral factor that indicates both professional interest and mixed conviction. Read More.
• Negative Sentiment: Insider sale: director/officer Tuyl Christopher Van sold 10,813 shares at an average price of $26.91 (transaction disclosed 12/18), reducing his stake by ~6.7%. Insider selling can raise short‑term concern about insider conviction, though the insider still holds a substantial position. Read More.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Guggenheim reiterated a “buy” rating and set a $41.00 target price on shares of Immunovant in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research report on Tuesday, October 14th. JPMorgan Chase & Co. decreased their target price on shares of Immunovant from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, September 30th. Truist Financial began coverage on shares of Immunovant in a research report on Tuesday, October 14th. They issued a “hold” rating and a $16.00 target price for the company. Finally, The Goldman Sachs Group increased their price target on shares of Immunovant from $18.00 to $28.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Immunovant currently has an average rating of “Moderate Buy” and a consensus target price of $27.63.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Baker BROS. Advisors LP grew its stake in shares of Immunovant by 219.6% during the first quarter. Baker BROS. Advisors LP now owns 5,457,881 shares of the company’s stock worth $93,275,000 after buying an additional 3,750,000 shares during the last quarter. ADAR1 Capital Management LLC boosted its holdings in shares of Immunovant by 319.0% during the 3rd quarter. ADAR1 Capital Management LLC now owns 2,241,753 shares of the company’s stock valued at $36,137,000 after acquiring an additional 1,706,687 shares in the last quarter. Woodline Partners LP grew its position in Immunovant by 133.0% during the 1st quarter. Woodline Partners LP now owns 1,497,869 shares of the company’s stock worth $25,599,000 after acquiring an additional 855,143 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its position in Immunovant by 15.2% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 5,894,824 shares of the company’s stock worth $100,743,000 after acquiring an additional 777,590 shares during the last quarter. Finally, Norges Bank acquired a new position in Immunovant in the 2nd quarter worth about $11,003,000. Institutional investors and hedge funds own 47.08% of the company’s stock.

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.